拓新药业
(301089)
| 流通市值：31.58亿 | | | 总市值：43.92亿 |
| 流通股本：9097.63万 | | | 总股本：1.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 96,994,677.03 | 421,694,066.41 | 325,753,716.96 | 218,756,705.1 |
| 营业收入 | 96,994,677.03 | 421,694,066.41 | 325,753,716.96 | 218,756,705.1 |
| 二、营业总成本 | 104,540,673.11 | 444,664,721.27 | 349,459,875.73 | 230,768,163.87 |
| 营业成本 | 67,258,386.01 | 295,746,607.74 | 242,077,660.34 | 165,051,401.37 |
| 税金及附加 | 2,179,935.8 | 7,873,037.63 | 5,189,793.22 | 2,983,628.25 |
| 销售费用 | 2,421,618.47 | 12,953,053.38 | 9,524,506.16 | 6,026,921.16 |
| 管理费用 | 23,695,005.3 | 91,465,623.34 | 65,788,241.8 | 42,924,862.24 |
| 研发费用 | 9,124,533.9 | 40,046,804.25 | 28,913,083.62 | 16,168,269.04 |
| 财务费用 | -138,806.37 | -3,420,405.07 | -2,033,409.41 | -2,386,918.19 |
| 其中:利息费用 | 40,784.94 | 53,515.72 | - | - |
| 其中:利息收入 | 114,070.34 | 2,636,405.39 | 2,264,292.77 | 1,817,543.8 |
| 加:公允价值变动收益 | 361,471.24 | 875,756.43 | -463,661.31 | -544,779.12 |
| 加:投资收益 | 1,011,509.12 | 677,321.82 | 2,963,289.62 | 1,953,769.65 |
| 资产处置收益 | - | -5,674.6 | - | - |
| 资产减值损失(新) | - | -10,678,437.92 | - | - |
| 信用减值损失(新) | 373,088.18 | -4,097,878.88 | 3,156,184.84 | 2,418,933.91 |
| 其他收益 | 2,065,448.22 | 12,481,393.24 | 10,901,554.5 | 7,034,864.21 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -3,734,479.32 | -23,718,174.77 | -7,148,791.12 | -1,148,670.12 |
| 加:营业外收入 | 19,762.83 | 195,370.83 | 148,190.73 | 83,163.16 |
| 减:营业外支出 | 253,554.04 | 4,209,682.55 | 3,896,564.18 | 267,749.53 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -3,968,270.53 | -27,732,486.49 | -10,897,164.57 | -1,333,256.49 |
| 减:所得税费用 | -403,529.84 | -7,847,617.57 | -8,243,385.44 | 446,066.6 |
| 六、净利润 | -3,564,740.69 | -19,884,868.92 | -2,653,779.13 | -1,779,323.09 |
| 持续经营净利润 | -3,564,740.69 | -19,884,868.92 | -2,653,779.13 | -1,779,323.09 |
| 归属于母公司股东的净利润 | -3,564,740.69 | -19,884,868.92 | -2,653,779.13 | -1,779,323.09 |
| (一)基本每股收益 | -0.03 | -0.16 | -0.02 | -0.01 |
| (二)稀释每股收益 | -0.03 | -0.16 | -0.02 | -0.01 |
| 八、其他综合收益 | - | 769,185.76 | - | - |
| 归属于母公司股东的其他综合收益 | - | 769,185.76 | - | - |
| 九、综合收益总额 | -3,564,740.69 | -19,115,683.16 | -2,653,779.13 | -1,779,323.09 |
| 归属于母公司股东的综合收益总额 | -3,564,740.69 | -19,115,683.16 | -2,653,779.13 | -1,779,323.09 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |